Frequently asked questions

Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening blood disorder. You may hear your doctor or some people refer to it as TTP. This is a general term. The 2 main types of TTP are inherited and acquired; however, 95% of all TTP cases are acquired.

Acquired: Describes a condition that is developed later in life. It may be unknown why aTTP is developed.

Thrombotic: Refers to the small blood clots that form inside blood vessels.

Thrombocytopenic: Means having a low platelet count.

Purpura: Red- or purple-colored spots on the skin that do not go away when pressure is applied. It may look like a bruise.

TTP=thrombotic thrombocytopenic purpura.

CABLIVI is a new treatment for aTTP. CABLIVI is used together with a procedure called plasma exchange and medication called immunosuppressive therapy to treat aTTP in adults. It is intended to prevent your body from forming dangerous blood clots during an aTTP episode.

aTTP=acquired thrombotic thrombocytopenic purpura.

CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with aTTP, in combination with plasma exchange and immunosuppressive therapy.

aTTP=acquired thrombotic thrombocytopenic purpura.

CABLIVI is used together with a procedure called plasma exchange and medication called immunosuppressive therapy to treat aTTP in adults.

CABLIVI has an active ingredient called caplacizumab-yhdp (cap-luh-siz-uh-mab). It is a small protein that is intended to prevent your body from forming dangerous blood clots during an aTTP episode.

aTTP=acquired thrombotic thrombocytopenic purpura.

CABLIVI treatment starts in the hospital with plasma exchange, then continues at home for at least 30 days after daily plasma exchange ends.

Keep taking CABLIVI until your doctor tells you to stop. Your doctor may decide you need to take CABLIVI for more than 30 days. This additional period may last up to 28 days. Your doctor may order additional blood tests, including a test to measure your ADAMTS13 level, an important marker of aTTP. This test may help your doctor decide when you no longer need CABLIVI.

aTTP=acquired thrombotic thrombocytopenic purpura.

CABLIVI treatment starts in the hospital with plasma exchange. Your first dose of CABLIVI will be a bolus IV injection before you receive your first plasma exchange. Every day after plasma exchange, CABLIVI will be given as an injection into the skin of your stomach.

IV=intravenous.

Taking CABLIVI daily, as directed by your doctor, is key for successful treatment. However, if you miss a dose, do the following:

  • During your plasma exchange sessions: Take CABLIVI as soon as possible
  • After you’re no longer on plasma exchange: Take CABLIVI daily within 12 hours of your scheduled time. After 12 hours, skip the dose and take the next scheduled dose

CABLIVI can cause side effects, although not everyone will experience them. In clinical studies, the most common side effects included nosebleeds, headaches, and bleeding from gums.

Because CABLIVI works by stopping the formation of blood clots, it may affect normal blood clotting and increase the risk of severe bleeding. In clinical studies, severe bleeding, nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects.

Contact your doctor immediately if excessive bleeding or bruising happens. Your doctor will decide on next steps.

Tell your doctor if you have a medical condition such as a bleeding disorder. You may have a higher risk of bleeding if you have a bleeding disorder (such as hemophilia) or if you take other medicines that increase your risk of bleeding (such as anticoagulants).

CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.

With CABLIVI Patient Solutions, support is available to cover the cost of CABLIVI’s co-pay or co-insurance for qualified, commercially insured patients, up to the program maximum.* CABLIVI will be provided at no cost to eligible underinsured or uninsured patients.

*This offer is not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, Veterans Affairs, Department of Defense, TRICARE, or similar federal or state programs.

Approval is not guaranteed. Sanofi Genzyme reserves the right to modify or discontinue the programs at any time.

Every insurance plan is different, so you will need to contact your insurance company to learn about your coverage options.

With CABLIVI Patient Solutions, support is available to cover the cost of CABLIVI’s co-pay or co-insurance for qualified, commercially insured patients, up to the program maximum.* CABLIVI will be provided at no cost to eligible underinsured or uninsured patients.

*This offer is not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, Veterans Affairs, Department of Defense, TRICARE, or similar federal or state programs.

Approval is not guaranteed. Sanofi Genzyme reserves the right to modify or discontinue the programs at any time.

Fill out our Stay Connected form to learn more about CABLIVI and aTTP.

aTTP=acquired thrombotic thrombocytopenic purpura.

For questions specific to your treatment and how you are doing, talk to your doctor.

For questions about CABLIVI services, CABLIVI Patient Solutions is available Monday through Friday, 8:00 AM to 8:00 PM ET, at 1-855-724-7222. Pharmacists are available 24 hours a day, 7 days a week.

Taking CABLIVI once a day is key for successful treatment. However, if you miss a dose, do the following:

  • During your plasma exchange sessions: Take CABLIVI as soon as possible
  • After you’re no longer on plasma exchange: Take CABLIVI daily within 12 hours of your scheduled time. After 12 hours, skip the dose and take the next scheduled dose

You should inject only one (1) vial of CABLIVI at a time, as recommended by your doctor. If you have accidentally used more than this, don’t inject any more and call your doctor right away.

Talk to your doctor before you stop treatment with CABLIVI. Do not stop treatment, even if you start to feel better, as stopping treatment too early could cause you to have another aTTP episode.

aTTP=acquired thrombotic thrombocytopenic purpura.

IMPORTANT SAFETY INFORMATION

Who should not take CABLIVI?

Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?

Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take.

Talk to your doctor before scheduling any surgery, medical or dental procedure.

What are the possible side effects of CABLIVI?

CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. Contact your doctor immediately if excessive bleeding or bruising occur.

You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants.

CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.

The most common side effects include nosebleed, headache and bleeding gums.

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.

INDICATION

What is CABLIVI?

CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Back to the top